{"nctId":"NCT04740905","briefTitle":"A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion","startDateStruct":{"date":"2021-03-02","type":"ACTUAL"},"conditions":["Macular Edema","Branch Retinal Vein Occlusion"],"count":553,"armGroups":[{"label":"Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)","type":"EXPERIMENTAL","interventionNames":["Drug: Faricimab","Procedure: Sham Procedure"]},{"label":"Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Faricimab","Drug: Aflibercept","Procedure: Sham Procedure"]}],"interventions":[{"name":"Faricimab","otherNames":["VABYSMO®","faricimab-svoa","RO6867461","RG7716"]},{"name":"Aflibercept","otherNames":["Eylea"]},{"name":"Sham Procedure","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Foveal center-involved macular edema due to branch retinal vein occlusion (BRVO), diagnosed no longer than 4 months prior to the screening visit\n* Best-corrected visual acuity (BCVA) of 73 to 19 letters, inclusive (20/40 to 20/400 approximate Snellen equivalent) on Day 1\n* Sufficiently clear ocular media and adequate pupillary dilatation to allow acquisition of good quality retinal images to confirm diagnosis\n* For women of childbearing potential: agreement to remain abstinent or use contraception, and agreement to refrain from donating eggs during the treatment period and for 3 months after the final dose of study treatment\n\nExclusion Criteria:\n\n* Any major illness or major surgical procedure within 1 month before screening\n* Uncontrolled blood pressure\n* Stroke (cerebral vascular accident) or myocardial infarction within 6 months prior to Day 1\n* Pregnant or breastfeeding, or intending to become pregnant during the study\n\nOcular Exclusion Criteria for Study Eye:\n\n* History of previous episodes of macular edema due to RVO or persistent macular edema due to RVO diagnosed more than 4 months before screening\n* Any current ocular condition which, in the opinion of the investigator, is currently causing or could be expected to contribute to irreversible vision loss due to a cause other than macular edema due to RVO in the study eye (e.g., ischemic maculopathy, Irvine-Gass syndrome, foveal atrophy, foveal fibrosis, pigment abnormalities, dense subfoveal hard exudates, or other non-retinal conditions)\n* Macular laser (focal/grid) in the study eye at any time prior to Day 1\n* Panretinal photocoagulation in the study eye within 3 months prior to Day 1 or anticipated within 3 months of study start on Day 1\n* Any prior or current treatment for macular edema; macular neovascularization, including diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD); and vitreomacular-interface abnormalities, including, but not restricted to, IVT treatment with anti-VEGF, steroids, tissue plasminogen activator, ocriplasmin, C3F8, air or periocular injection\n* Any prior intervention with verteporfin photodynamic therapy, diode laser, transpupillary thermotherapy, or vitreo-retinal surgery including sheatotomy\n* Any prior steroid implant use including dexamethasone intravitreal implant (Ozurdex) and fluocinolone acetonide intravitreal implant (Iluvien)\n\nOcular Exclusion Criteria for Both Eyes:\n\n* Prior IVT administration of faricimab in either eye\n* History of idiopathic or autoimmune-associated uveitis in either eye\n* Active periocular, ocular or intraocular inflammation or infection (including suspected) in either eye on Day 1","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Part 1: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye at Week 24","description":"Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis included the categorical covariates of treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), and randomization stratification factors \\[baseline BCVA (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and rest of the world)\\] as fixed effects. An unstructured covariance structure was used. Missing data were implicitly imputed by MMRM model assuming missing at random. Treatment policy strategy (i.e., all observed values used) was applied to all intercurrent events (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). 95% CI is a rounding of 95.03% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.9","spread":null},{"groupId":"OG001","value":"17.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1: Change From Baseline in BCVA in the Study Eye at Specified Timepoints Through Week 24","description":"Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis included the categorical covariates of treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), and randomization stratification factors \\[baseline BCVA (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and rest of the world)\\] as fixed effects. An unstructured covariance structure was used. Missing data were implicitly imputed by MMRM model assuming missing at random. Treatment policy strategy (i.e., all observed values used) was applied to all intercurrent events (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). 95% CI is a rounding of 95.03% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.5","spread":null},{"groupId":"OG001","value":"12.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.7","spread":null},{"groupId":"OG001","value":"15.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.1","spread":null},{"groupId":"OG001","value":"15.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.5","spread":null},{"groupId":"OG001","value":"16.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.3","spread":null},{"groupId":"OG001","value":"17.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.9","spread":null},{"groupId":"OG001","value":"17.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1: Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye at Week 24","description":"Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \\[baseline BCVA (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and rest of the world)\\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.1","spread":null},{"groupId":"OG001","value":"60.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1: Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24","description":"Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \\[baseline BCVA (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and rest of the world)\\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.3","spread":null},{"groupId":"OG001","value":"36.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.2","spread":null},{"groupId":"OG001","value":"46.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.0","spread":null},{"groupId":"OG001","value":"52.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.6","spread":null},{"groupId":"OG001","value":"56.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.1","spread":null},{"groupId":"OG001","value":"58.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.1","spread":null},{"groupId":"OG001","value":"60.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1: Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24","description":"Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \\[baseline BCVA (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and rest of the world)\\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.5","spread":null},{"groupId":"OG001","value":"59.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.1","spread":null},{"groupId":"OG001","value":"69.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","spread":null},{"groupId":"OG001","value":"74.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.1","spread":null},{"groupId":"OG001","value":"76.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.3","spread":null},{"groupId":"OG001","value":"79.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.5","spread":null},{"groupId":"OG001","value":"77.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1: Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24","description":"Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \\[baseline BCVA (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and rest of the world)\\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.7","spread":null},{"groupId":"OG001","value":"79.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.0","spread":null},{"groupId":"OG001","value":"88.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.0","spread":null},{"groupId":"OG001","value":"87.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.9","spread":null},{"groupId":"OG001","value":"88.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.4","spread":null},{"groupId":"OG001","value":"90.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.9","spread":null},{"groupId":"OG001","value":"89.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1: Percentage of Participants Gaining >0 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24","description":"Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \\[baseline BCVA (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and rest of the world)\\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.2","spread":null},{"groupId":"OG001","value":"93.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.7","spread":null},{"groupId":"OG001","value":"96.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.9","spread":null},{"groupId":"OG001","value":"94.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.8","spread":null},{"groupId":"OG001","value":"94.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.9","spread":null},{"groupId":"OG001","value":"96.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.4","spread":null},{"groupId":"OG001","value":"95.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1: Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24","description":"Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \\[baseline BCVA (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and rest of the world)\\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.3","spread":null},{"groupId":"OG001","value":"98.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.3","spread":null},{"groupId":"OG001","value":"98.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.3","spread":null},{"groupId":"OG001","value":"98.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.3","spread":null},{"groupId":"OG001","value":"98.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","spread":null},{"groupId":"OG001","value":"98.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","spread":null},{"groupId":"OG001","value":"98.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1: Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24","description":"Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \\[baseline BCVA (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and rest of the world)\\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.5","spread":null},{"groupId":"OG001","value":"98.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.5","spread":null},{"groupId":"OG001","value":"98.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.5","spread":null},{"groupId":"OG001","value":"98.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.5","spread":null},{"groupId":"OG001","value":"98.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.3","spread":null},{"groupId":"OG001","value":"98.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","spread":null},{"groupId":"OG001","value":"98.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1: Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24","description":"Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \\[baseline BCVA (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and rest of the world)\\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.1","spread":null},{"groupId":"OG001","value":"98.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.8","spread":null},{"groupId":"OG001","value":"98.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.8","spread":null},{"groupId":"OG001","value":"98.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.8","spread":null},{"groupId":"OG001","value":"98.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.5","spread":null},{"groupId":"OG001","value":"97.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.6","spread":null},{"groupId":"OG001","value":"97.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1: Percentage of Participants Achieving ≥84 Letters in BCVA (20/20 Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 24","description":"Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \\[baseline BCVA (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and rest of the world)\\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.7","spread":null},{"groupId":"OG001","value":"8.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.1","spread":null},{"groupId":"OG001","value":"15.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.6","spread":null},{"groupId":"OG001","value":"20.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.4","spread":null},{"groupId":"OG001","value":"22.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.7","spread":null},{"groupId":"OG001","value":"23.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.9","spread":null},{"groupId":"OG001","value":"23.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1: Percentage of Participants Achieving ≥69 Letters in BCVA (20/40 or Better Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 24","description":"Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \\[baseline BCVA (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and rest of the world)\\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.6","spread":null},{"groupId":"OG001","value":"62.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.9","spread":null},{"groupId":"OG001","value":"70.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.0","spread":null},{"groupId":"OG001","value":"69.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.2","spread":null},{"groupId":"OG001","value":"72.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.3","spread":null},{"groupId":"OG001","value":"76.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.7","spread":null},{"groupId":"OG001","value":"76.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1: Percentage of Participants With ≤38 Letters in BCVA (20/200 or Worse Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 24","description":"Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (\\>38 and ≤38 letters) and region (U.S. and Canada, Asia, and rest of the world). All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":null},{"groupId":"OG001","value":"1.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":null},{"groupId":"OG001","value":"1.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":null},{"groupId":"OG001","value":"1.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":null},{"groupId":"OG001","value":"1.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":null},{"groupId":"OG001","value":"1.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":null},{"groupId":"OG001","value":"1.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1: Change From Baseline in Central Subfield Thickness in the Study Eye at Specified Timepoints Through Week 24","description":"Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE) using optical coherence tomography (OCT), as assessed by the central reading center. The Mixed Model of Repeated Measures (MMRM) analysis included the categorical covariates of treatment arm, visit, visit-by-treatment arm interaction, baseline CST (continuous), and randomization stratification factors \\[baseline BCVA (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and rest of the world)\\] as fixed effects. An unstructured covariance structure was used. Missing data were implicitly imputed by MMRM model assuming missing at random. Treatment policy strategy (i.e., all observed values used) was applied to all intercurrent events (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). 95% CI is a rounding of 95.03% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-283.9","spread":null},{"groupId":"OG001","value":"-281.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-299.4","spread":null},{"groupId":"OG001","value":"-296.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-304.4","spread":null},{"groupId":"OG001","value":"-298.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-306.1","spread":null},{"groupId":"OG001","value":"-301.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-307.3","spread":null},{"groupId":"OG001","value":"-302.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-311.4","spread":null},{"groupId":"OG001","value":"-304.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1: Percentage of Participants With Absence of Macular Edema in the Study Eye at Specified Timepoints Through Week 24","description":"Absence of diabetic macular edema was defined as achieving a central subfield thickness of \\<325 microns in the study eye. Central subfield thickness was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \\[baseline BCVA (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and rest of the world)\\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.8","spread":null},{"groupId":"OG001","value":"88.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.5","spread":null},{"groupId":"OG001","value":"93.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.4","spread":null},{"groupId":"OG001","value":"92.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.3","spread":null},{"groupId":"OG001","value":"93.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.0","spread":null},{"groupId":"OG001","value":"94.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.3","spread":null},{"groupId":"OG001","value":"93.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1: Percentage of Participants With Absence of Intraretinal Fluid in the Study Eye at Specified Timepoints Through Week 24","description":"Intraretinal fluid was measured in the study eye using optical coherence tomography (OCT) in the central subfield (center 1 mm) by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \\[baseline BCVA (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and rest of the world)\\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.1","spread":null},{"groupId":"OG001","value":"54.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.8","spread":null},{"groupId":"OG001","value":"57.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.3","spread":null},{"groupId":"OG001","value":"56.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.9","spread":null},{"groupId":"OG001","value":"72.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.1","spread":null},{"groupId":"OG001","value":"66.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.5","spread":null},{"groupId":"OG001","value":"66.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1: Percentage of Participants With Absence of Subretinal Fluid in the Study Eye at Specified Timepoints Through Week 24","description":"Subretinal fluid was measured in the study eye using optical coherence tomography (OCT) in the central subfield (center 1 mm) by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \\[baseline BCVA (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and rest of the world)\\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.1","spread":null},{"groupId":"OG001","value":"72.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.1","spread":null},{"groupId":"OG001","value":"91.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.4","spread":null},{"groupId":"OG001","value":"97.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.3","spread":null},{"groupId":"OG001","value":"96.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.2","spread":null},{"groupId":"OG001","value":"97.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.3","spread":null},{"groupId":"OG001","value":"90.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1: Percentage of Participants With Absence of Intraretinal Fluid and Subretinal Fluid in the Study Eye at Specified Timepoints Through Week 24","description":"Intraretinal fluid and subretinal fluid were measured in the study eye using optical coherence tomography (OCT) in the central subfield (center 1 mm) by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \\[baseline BCVA (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and rest of the world)\\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.8","spread":null},{"groupId":"OG001","value":"40.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.9","spread":null},{"groupId":"OG001","value":"54.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.8","spread":null},{"groupId":"OG001","value":"56.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.1","spread":null},{"groupId":"OG001","value":"72.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.0","spread":null},{"groupId":"OG001","value":"66.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.3","spread":null},{"groupId":"OG001","value":"61.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1: Change From Baseline in National Eye Institute 25-Item Visual Functioning Questionnaire (NEI VFQ-25) Composite Score at Week 24","description":"The NEI VFQ-25 captures a patient's perception of vision-related functioning and vision-related quality of life. The core measure includes 25 items that comprise 11 vision-related subscales and 1 item on general health. The composite score ranges from 0 to 100, with higher scores indicating better vision-related functioning. For the ANCOVA analysis, the model uses the non-missing change from baseline in BCVA at Weeks 24 as the response variables adjusted for the treatment group, baseline NEI VFQ-25 Composite Score (continuous), baseline BCVA score (≥55 and ≤54 letters) and region (U.S. and Canada, Asia, and the rest of the world). Observed NEI VFQ-25 assessments were used regardless of the occurrence of intercurrent events. Missing data were not imputed. 95% CI is a rounding of 95.03% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":null},{"groupId":"OG001","value":"5.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Parts 1 and 2: Change From Baseline in BCVA in the Study Eye at Specified Timepoints Through Week 72","description":"Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis included the categorical covariates of treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), and randomization stratification factors \\[baseline BCVA (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and rest of the world)\\] as fixed effects. An unstructured covariance structure was used. Missing data were implicitly imputed by MMRM model assuming missing at random. Treatment policy strategy (i.e., all observed values used) was applied to all intercurrent events (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). 95% CI is a rounding of 95.03% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.5","spread":null},{"groupId":"OG001","value":"12.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.7","spread":null},{"groupId":"OG001","value":"15.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.1","spread":null},{"groupId":"OG001","value":"15.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.5","spread":null},{"groupId":"OG001","value":"16.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.3","spread":null},{"groupId":"OG001","value":"17.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.8","spread":null},{"groupId":"OG001","value":"17.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.5","spread":null},{"groupId":"OG001","value":"17.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.2","spread":null},{"groupId":"OG001","value":"17.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.3","spread":null},{"groupId":"OG001","value":"18.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.3","spread":null},{"groupId":"OG001","value":"17.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.1","spread":null},{"groupId":"OG001","value":"17.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.0","spread":null},{"groupId":"OG001","value":"18.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.0","spread":null},{"groupId":"OG001","value":"18.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.3","spread":null},{"groupId":"OG001","value":"18.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.0","spread":null},{"groupId":"OG001","value":"18.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.9","spread":null},{"groupId":"OG001","value":"18.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.1","spread":null},{"groupId":"OG001","value":"18.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.4","spread":null},{"groupId":"OG001","value":"18.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Parts 1 and 2: Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72","description":"Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \\[baseline BCVA (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and rest of the world)\\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.3","spread":null},{"groupId":"OG001","value":"36.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.2","spread":null},{"groupId":"OG001","value":"46.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.0","spread":null},{"groupId":"OG001","value":"52.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.6","spread":null},{"groupId":"OG001","value":"56.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.1","spread":null},{"groupId":"OG001","value":"58.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.1","spread":null},{"groupId":"OG001","value":"60.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.8","spread":null},{"groupId":"OG001","value":"61.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.0","spread":null},{"groupId":"OG001","value":"61.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.2","spread":null},{"groupId":"OG001","value":"62.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.8","spread":null},{"groupId":"OG001","value":"61.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.5","spread":null},{"groupId":"OG001","value":"58.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.1","spread":null},{"groupId":"OG001","value":"60.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.2","spread":null},{"groupId":"OG001","value":"64.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.9","spread":null},{"groupId":"OG001","value":"63.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.6","spread":null},{"groupId":"OG001","value":"62.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.9","spread":null},{"groupId":"OG001","value":"65.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.0","spread":null},{"groupId":"OG001","value":"64.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.3","spread":null},{"groupId":"OG001","value":"66.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Parts 1 and 2: Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72","description":"Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \\[baseline BCVA (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and rest of the world)\\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.5","spread":null},{"groupId":"OG001","value":"59.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.1","spread":null},{"groupId":"OG001","value":"69.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","spread":null},{"groupId":"OG001","value":"74.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.1","spread":null},{"groupId":"OG001","value":"76.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.3","spread":null},{"groupId":"OG001","value":"79.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.5","spread":null},{"groupId":"OG001","value":"77.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.1","spread":null},{"groupId":"OG001","value":"76.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.5","spread":null},{"groupId":"OG001","value":"78.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.7","spread":null},{"groupId":"OG001","value":"78.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.5","spread":null},{"groupId":"OG001","value":"76.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.4","spread":null},{"groupId":"OG001","value":"76.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.7","spread":null},{"groupId":"OG001","value":"79.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.8","spread":null},{"groupId":"OG001","value":"80.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.7","spread":null},{"groupId":"OG001","value":"78.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.3","spread":null},{"groupId":"OG001","value":"80.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.9","spread":null},{"groupId":"OG001","value":"78.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.9","spread":null},{"groupId":"OG001","value":"77.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.4","spread":null},{"groupId":"OG001","value":"79.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Parts 1 and 2: Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72","description":"Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \\[baseline BCVA (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and rest of the world)\\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.7","spread":null},{"groupId":"OG001","value":"79.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.0","spread":null},{"groupId":"OG001","value":"88.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.0","spread":null},{"groupId":"OG001","value":"87.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.9","spread":null},{"groupId":"OG001","value":"88.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.4","spread":null},{"groupId":"OG001","value":"90.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.9","spread":null},{"groupId":"OG001","value":"89.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.1","spread":null},{"groupId":"OG001","value":"87.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.5","spread":null},{"groupId":"OG001","value":"87.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.4","spread":null},{"groupId":"OG001","value":"90.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.2","spread":null},{"groupId":"OG001","value":"90.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.1","spread":null},{"groupId":"OG001","value":"88.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.4","spread":null},{"groupId":"OG001","value":"90.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.9","spread":null},{"groupId":"OG001","value":"88.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.0","spread":null},{"groupId":"OG001","value":"87.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.9","spread":null},{"groupId":"OG001","value":"88.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.6","spread":null},{"groupId":"OG001","value":"87.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.5","spread":null},{"groupId":"OG001","value":"87.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.8","spread":null},{"groupId":"OG001","value":"87.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Parts 1 and 2: Percentage of Participants Gaining >0 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72","description":"Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \\[baseline BCVA (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and rest of the world)\\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.2","spread":null},{"groupId":"OG001","value":"93.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.7","spread":null},{"groupId":"OG001","value":"96.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.9","spread":null},{"groupId":"OG001","value":"94.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.8","spread":null},{"groupId":"OG001","value":"94.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.9","spread":null},{"groupId":"OG001","value":"96.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.4","spread":null},{"groupId":"OG001","value":"95.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.3","spread":null},{"groupId":"OG001","value":"95.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.0","spread":null},{"groupId":"OG001","value":"95.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.2","spread":null},{"groupId":"OG001","value":"94.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.6","spread":null},{"groupId":"OG001","value":"95.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.3","spread":null},{"groupId":"OG001","value":"94.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.6","spread":null},{"groupId":"OG001","value":"96.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.8","spread":null},{"groupId":"OG001","value":"94.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.1","spread":null},{"groupId":"OG001","value":"95.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.6","spread":null},{"groupId":"OG001","value":"94.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.9","spread":null},{"groupId":"OG001","value":"94.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.5","spread":null},{"groupId":"OG001","value":"93.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.6","spread":null},{"groupId":"OG001","value":"93.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Parts 1 and 2: Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72","description":"Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \\[baseline BCVA (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and rest of the world)\\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.3","spread":null},{"groupId":"OG001","value":"98.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.3","spread":null},{"groupId":"OG001","value":"98.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.3","spread":null},{"groupId":"OG001","value":"98.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.3","spread":null},{"groupId":"OG001","value":"98.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","spread":null},{"groupId":"OG001","value":"98.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","spread":null},{"groupId":"OG001","value":"98.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","spread":null},{"groupId":"OG001","value":"98.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","spread":null},{"groupId":"OG001","value":"98.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","spread":null},{"groupId":"OG001","value":"98.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.9","spread":null},{"groupId":"OG001","value":"98.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.3","spread":null},{"groupId":"OG001","value":"98.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.3","spread":null},{"groupId":"OG001","value":"98.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.6","spread":null},{"groupId":"OG001","value":"98.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.9","spread":null},{"groupId":"OG001","value":"98.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.3","spread":null},{"groupId":"OG001","value":"98.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.9","spread":null},{"groupId":"OG001","value":"97.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.9","spread":null},{"groupId":"OG001","value":"98.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.9","spread":null},{"groupId":"OG001","value":"98.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Parts 1 and 2: Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72","description":"Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \\[baseline BCVA (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and rest of the world)\\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.5","spread":null},{"groupId":"OG001","value":"98.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.5","spread":null},{"groupId":"OG001","value":"98.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.5","spread":null},{"groupId":"OG001","value":"98.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.5","spread":null},{"groupId":"OG001","value":"98.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.3","spread":null},{"groupId":"OG001","value":"98.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","spread":null},{"groupId":"OG001","value":"98.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","spread":null},{"groupId":"OG001","value":"98.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.3","spread":null},{"groupId":"OG001","value":"98.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","spread":null},{"groupId":"OG001","value":"98.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.9","spread":null},{"groupId":"OG001","value":"98.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.3","spread":null},{"groupId":"OG001","value":"98.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.9","spread":null},{"groupId":"OG001","value":"98.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.6","spread":null},{"groupId":"OG001","value":"98.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.9","spread":null},{"groupId":"OG001","value":"97.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.9","spread":null},{"groupId":"OG001","value":"98.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.6","spread":null},{"groupId":"OG001","value":"97.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.6","spread":null},{"groupId":"OG001","value":"97.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.2","spread":null},{"groupId":"OG001","value":"97.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Parts 1 and 2: Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72","description":"Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \\[baseline BCVA (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and rest of the world)\\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.1","spread":null},{"groupId":"OG001","value":"98.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.8","spread":null},{"groupId":"OG001","value":"98.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.8","spread":null},{"groupId":"OG001","value":"98.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.8","spread":null},{"groupId":"OG001","value":"98.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.5","spread":null},{"groupId":"OG001","value":"97.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.6","spread":null},{"groupId":"OG001","value":"97.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.2","spread":null},{"groupId":"OG001","value":"97.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.6","spread":null},{"groupId":"OG001","value":"97.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.2","spread":null},{"groupId":"OG001","value":"97.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.1","spread":null},{"groupId":"OG001","value":"97.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.6","spread":null},{"groupId":"OG001","value":"97.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.1","spread":null},{"groupId":"OG001","value":"97.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.1","spread":null},{"groupId":"OG001","value":"97.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.5","spread":null},{"groupId":"OG001","value":"97.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.8","spread":null},{"groupId":"OG001","value":"96.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.1","spread":null},{"groupId":"OG001","value":"96.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.1","spread":null},{"groupId":"OG001","value":"97.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.1","spread":null},{"groupId":"OG001","value":"96.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Parts 1 and 2: Percentage of Participants Achieving ≥84 Letters in BCVA (20/20 Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 72","description":"Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \\[baseline BCVA (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and rest of the world)\\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.7","spread":null},{"groupId":"OG001","value":"8.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.1","spread":null},{"groupId":"OG001","value":"15.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.6","spread":null},{"groupId":"OG001","value":"20.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.4","spread":null},{"groupId":"OG001","value":"22.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.7","spread":null},{"groupId":"OG001","value":"23.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.9","spread":null},{"groupId":"OG001","value":"23.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.0","spread":null},{"groupId":"OG001","value":"25.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.1","spread":null},{"groupId":"OG001","value":"23.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.1","spread":null},{"groupId":"OG001","value":"25.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.9","spread":null},{"groupId":"OG001","value":"22.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.8","spread":null},{"groupId":"OG001","value":"24.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.0","spread":null},{"groupId":"OG001","value":"25.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.8","spread":null},{"groupId":"OG001","value":"25.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.1","spread":null},{"groupId":"OG001","value":"22.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.6","spread":null},{"groupId":"OG001","value":"25.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.1","spread":null},{"groupId":"OG001","value":"24.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.4","spread":null},{"groupId":"OG001","value":"25.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.4","spread":null},{"groupId":"OG001","value":"24.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Parts 1 and 2: Percentage of Participants Achieving ≥69 Letters in BCVA (20/40 or Better Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 72","description":"Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \\[baseline BCVA (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and rest of the world)\\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.6","spread":null},{"groupId":"OG001","value":"62.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.9","spread":null},{"groupId":"OG001","value":"70.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.0","spread":null},{"groupId":"OG001","value":"69.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.2","spread":null},{"groupId":"OG001","value":"72.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.3","spread":null},{"groupId":"OG001","value":"76.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.7","spread":null},{"groupId":"OG001","value":"76.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.3","spread":null},{"groupId":"OG001","value":"75.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.9","spread":null},{"groupId":"OG001","value":"75.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.2","spread":null},{"groupId":"OG001","value":"77.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.5","spread":null},{"groupId":"OG001","value":"76.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.9","spread":null},{"groupId":"OG001","value":"76.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.2","spread":null},{"groupId":"OG001","value":"79.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.7","spread":null},{"groupId":"OG001","value":"80.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.2","spread":null},{"groupId":"OG001","value":"79.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.2","spread":null},{"groupId":"OG001","value":"79.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.6","spread":null},{"groupId":"OG001","value":"81.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.6","spread":null},{"groupId":"OG001","value":"80.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.0","spread":null},{"groupId":"OG001","value":"79.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Parts 1 and 2: Percentage of Participants With ≤38 Letters in BCVA (20/200 or Worse Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 72","description":"Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (\\>38 and ≤38 letters) and region (U.S. and Canada, Asia, and rest of the world). All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":null},{"groupId":"OG001","value":"1.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":null},{"groupId":"OG001","value":"1.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":null},{"groupId":"OG001","value":"1.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":null},{"groupId":"OG001","value":"1.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":null},{"groupId":"OG001","value":"1.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":null},{"groupId":"OG001","value":"1.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"1.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":null},{"groupId":"OG001","value":"1.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null},{"groupId":"OG001","value":"1.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":null},{"groupId":"OG001","value":"1.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":null},{"groupId":"OG001","value":"1.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":null},{"groupId":"OG001","value":"2.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":null},{"groupId":"OG001","value":"2.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":null},{"groupId":"OG001","value":"2.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":null},{"groupId":"OG001","value":"2.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":null},{"groupId":"OG001","value":"2.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":null},{"groupId":"OG001","value":"1.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":null},{"groupId":"OG001","value":"2.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Parts 1 and 2: Change From Baseline in NEI VFQ-25 Questionnaire Composite Score at Specified Timepoints Through Week 72","description":"The NEI VFQ-25 captures a patient's perception of vision-related functioning and vision-related quality of life. The core measure includes 25 items that comprise 11 vision-related subscales and 1 item on general health. The composite score ranges from 0 to 100, with higher scores indicating better vision-related functioning. For the MMRM analysis, the model adjusted for the treatment group, visit, visit-by-treatment group interaction, baseline NEI VFQ-25 Composite Score continuous), baseline BCVA score (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and the rest of the world). Observed NEI VFQ-25 assessments were used regardless of the occurrence of intercurrent events. Missing data were implicitly imputed. Invalid BCVA values were excluded. 95% CI is a rounding of 95.03% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":null},{"groupId":"OG001","value":"5.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.4","spread":null},{"groupId":"OG001","value":"6.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":null},{"groupId":"OG001","value":"7.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Parts 1 and 2: Change From Baseline in Central Subfield Thickness in the Study Eye at Specified Timepoints Through Week 72","description":"Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE) using optical coherence tomography (OCT), as assessed by the central reading center. The Mixed Model of Repeated Measures (MMRM) analysis included the categorical covariates of treatment arm, visit, visit-by-treatment arm interaction, baseline CST (continuous), and randomization stratification factors \\[baseline BCVA (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and rest of the world)\\] as fixed effects. An unstructured covariance structure was used. Missing data were implicitly imputed by MMRM model assuming missing at random. Treatment policy strategy (i.e., all observed values used) was applied to all intercurrent events (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). 95% CI is a rounding of 95.03% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-287.3","spread":null},{"groupId":"OG001","value":"-284.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-302.9","spread":null},{"groupId":"OG001","value":"-300.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-307.8","spread":null},{"groupId":"OG001","value":"-301.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-309.3","spread":null},{"groupId":"OG001","value":"-304.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-310.6","spread":null},{"groupId":"OG001","value":"-304.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-314.5","spread":null},{"groupId":"OG001","value":"-307.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-294.0","spread":null},{"groupId":"OG001","value":"-285.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-308.3","spread":null},{"groupId":"OG001","value":"-303.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-304.1","spread":null},{"groupId":"OG001","value":"-298.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-296.7","spread":null},{"groupId":"OG001","value":"-285.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-309.2","spread":null},{"groupId":"OG001","value":"-301.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-309.4","spread":null},{"groupId":"OG001","value":"-302.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-302.2","spread":null},{"groupId":"OG001","value":"-302.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-294.0","spread":null},{"groupId":"OG001","value":"-288.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-309.5","spread":null},{"groupId":"OG001","value":"-306.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-311.1","spread":null},{"groupId":"OG001","value":"-305.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-311.2","spread":null},{"groupId":"OG001","value":"-307.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-310.5","spread":null},{"groupId":"OG001","value":"-307.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Parts 1 and 2: Percentage of Participants With Absence of Macular Edema in the Study Eye at Specified Timepoints Through Week 72","description":"Absence of diabetic macular edema was defined as achieving a central subfield thickness of \\<325 microns in the study eye. Central subfield thickness was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \\[baseline BCVA (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and rest of the world)\\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.8","spread":null},{"groupId":"OG001","value":"88.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.5","spread":null},{"groupId":"OG001","value":"93.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.4","spread":null},{"groupId":"OG001","value":"92.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.3","spread":null},{"groupId":"OG001","value":"93.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.0","spread":null},{"groupId":"OG001","value":"94.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.6","spread":null},{"groupId":"OG001","value":"94.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.1","spread":null},{"groupId":"OG001","value":"86.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.6","spread":null},{"groupId":"OG001","value":"92.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.8","spread":null},{"groupId":"OG001","value":"90.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.5","spread":null},{"groupId":"OG001","value":"84.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.0","spread":null},{"groupId":"OG001","value":"92.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.9","spread":null},{"groupId":"OG001","value":"91.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.4","spread":null},{"groupId":"OG001","value":"91.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.5","spread":null},{"groupId":"OG001","value":"86.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.2","spread":null},{"groupId":"OG001","value":"93.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.3","spread":null},{"groupId":"OG001","value":"93.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.9","spread":null},{"groupId":"OG001","value":"92.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.2","spread":null},{"groupId":"OG001","value":"94.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Parts 1 and 2: Percentage of Participants With Absence of Intraretinal Fluid in the Study Eye at Specified Timepoints Through Week 72","description":"Intraretinal fluid was measured in the study eye using optical coherence tomography (OCT) in the central subfield (center 1 mm) by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \\[baseline BCVA (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and rest of the world)\\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.1","spread":null},{"groupId":"OG001","value":"54.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.8","spread":null},{"groupId":"OG001","value":"57.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.3","spread":null},{"groupId":"OG001","value":"56.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.9","spread":null},{"groupId":"OG001","value":"72.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.1","spread":null},{"groupId":"OG001","value":"66.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.9","spread":null},{"groupId":"OG001","value":"69.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.4","spread":null},{"groupId":"OG001","value":"47.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.1","spread":null},{"groupId":"OG001","value":"65.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.9","spread":null},{"groupId":"OG001","value":"56.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.8","spread":null},{"groupId":"OG001","value":"48.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.3","spread":null},{"groupId":"OG001","value":"63.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.1","spread":null},{"groupId":"OG001","value":"67.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.8","spread":null},{"groupId":"OG001","value":"56.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.4","spread":null},{"groupId":"OG001","value":"58.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","spread":null},{"groupId":"OG001","value":"72.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.8","spread":null},{"groupId":"OG001","value":"69.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.9","spread":null},{"groupId":"OG001","value":"68.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.8","spread":null},{"groupId":"OG001","value":"72.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Parts 1 and 2: Percentage of Participants With Absence of Subretinal Fluid in the Study Eye at Specified Timepoints Through Week 72","description":"Subretinal fluid was measured in the study eye using optical coherence tomography (OCT) in the central subfield (center 1 mm) by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \\[baseline BCVA (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and rest of the world)\\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.1","spread":null},{"groupId":"OG001","value":"72.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.1","spread":null},{"groupId":"OG001","value":"91.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.4","spread":null},{"groupId":"OG001","value":"97.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.3","spread":null},{"groupId":"OG001","value":"96.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.2","spread":null},{"groupId":"OG001","value":"97.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.3","spread":null},{"groupId":"OG001","value":"90.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.5","spread":null},{"groupId":"OG001","value":"91.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.4","spread":null},{"groupId":"OG001","value":"97.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.1","spread":null},{"groupId":"OG001","value":"96.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.8","spread":null},{"groupId":"OG001","value":"95.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.5","spread":null},{"groupId":"OG001","value":"95.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.1","spread":null},{"groupId":"OG001","value":"94.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.2","spread":null},{"groupId":"OG001","value":"97.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.3","spread":null},{"groupId":"OG001","value":"95.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.7","spread":null},{"groupId":"OG001","value":"96.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.2","spread":null},{"groupId":"OG001","value":"96.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.5","spread":null},{"groupId":"OG001","value":"97.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.4","spread":null},{"groupId":"OG001","value":"94.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Parts 1 and 2: Percentage of Participants With Absence of Intraretinal Fluid and Subretinal Fluid in the Study Eye at Specified Timepoints Through Week 72","description":"Intraretinal fluid and subretinal fluid were measured in the study eye using optical coherence tomography (OCT) in the central subfield (center 1 mm) by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \\[baseline BCVA (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and rest of the world)\\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.8","spread":null},{"groupId":"OG001","value":"40.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.9","spread":null},{"groupId":"OG001","value":"54.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.8","spread":null},{"groupId":"OG001","value":"56.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.1","spread":null},{"groupId":"OG001","value":"72.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.0","spread":null},{"groupId":"OG001","value":"66.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.4","spread":null},{"groupId":"OG001","value":"64.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.0","spread":null},{"groupId":"OG001","value":"46.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.4","spread":null},{"groupId":"OG001","value":"64.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.5","spread":null},{"groupId":"OG001","value":"54.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.4","spread":null},{"groupId":"OG001","value":"47.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.6","spread":null},{"groupId":"OG001","value":"63.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.7","spread":null},{"groupId":"OG001","value":"65.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.5","spread":null},{"groupId":"OG001","value":"55.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.0","spread":null},{"groupId":"OG001","value":"57.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.9","spread":null},{"groupId":"OG001","value":"70.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.4","spread":null},{"groupId":"OG001","value":"69.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.9","spread":null},{"groupId":"OG001","value":"68.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.7","spread":null},{"groupId":"OG001","value":"71.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 2: Change From Week 24 in BCVA in the Study Eye at Specified Timepoints Through Week 72","description":"Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis included the categorical covariates of treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), and randomization stratification factors \\[baseline BCVA (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and rest of the world)\\] as fixed effects. An unstructured covariance structure was used. Missing data were implicitly imputed by MMRM model assuming missing at random. Treatment policy strategy (i.e., all observed values used) was applied to all intercurrent events (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). 95% CI is a rounding of 95.03% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":null},{"groupId":"OG001","value":"-0.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"0.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"0.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"0.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"0.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"1.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":null},{"groupId":"OG001","value":"1.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":null},{"groupId":"OG001","value":"1.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":null},{"groupId":"OG001","value":"1.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 2: Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Week 24 in the Study Eye at Specified Timepoints Through Week 72","description":"Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \\[baseline BCVA (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and rest of the world)\\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.5","spread":null},{"groupId":"OG001","value":"84.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.1","spread":null},{"groupId":"OG001","value":"87.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.5","spread":null},{"groupId":"OG001","value":"88.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.5","spread":null},{"groupId":"OG001","value":"88.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.9","spread":null},{"groupId":"OG001","value":"86.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.5","spread":null},{"groupId":"OG001","value":"86.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.9","spread":null},{"groupId":"OG001","value":"87.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.0","spread":null},{"groupId":"OG001","value":"86.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.8","spread":null},{"groupId":"OG001","value":"87.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.5","spread":null},{"groupId":"OG001","value":"86.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.4","spread":null},{"groupId":"OG001","value":"87.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.4","spread":null},{"groupId":"OG001","value":"87.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 2: Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Week 24 in the Study Eye at Specified Timepoints Through Week 72","description":"Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \\[baseline BCVA (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and rest of the world)\\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.8","spread":null},{"groupId":"OG001","value":"82.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.8","spread":null},{"groupId":"OG001","value":"85.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.3","spread":null},{"groupId":"OG001","value":"87.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.7","spread":null},{"groupId":"OG001","value":"86.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.8","spread":null},{"groupId":"OG001","value":"85.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.4","spread":null},{"groupId":"OG001","value":"85.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.4","spread":null},{"groupId":"OG001","value":"85.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.2","spread":null},{"groupId":"OG001","value":"83.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.9","spread":null},{"groupId":"OG001","value":"83.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.9","spread":null},{"groupId":"OG001","value":"85.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.6","spread":null},{"groupId":"OG001","value":"85.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.6","spread":null},{"groupId":"OG001","value":"85.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 2: Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Week 24 in the Study Eye at Specified Timepoints Through Week 72","description":"Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \\[baseline BCVA (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and rest of the world)\\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.6","spread":null},{"groupId":"OG001","value":"73.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.0","spread":null},{"groupId":"OG001","value":"77.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.7","spread":null},{"groupId":"OG001","value":"79.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.6","spread":null},{"groupId":"OG001","value":"78.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null},{"groupId":"OG001","value":"76.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.6","spread":null},{"groupId":"OG001","value":"79.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.5","spread":null},{"groupId":"OG001","value":"79.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.4","spread":null},{"groupId":"OG001","value":"78.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.0","spread":null},{"groupId":"OG001","value":"77.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.9","spread":null},{"groupId":"OG001","value":"76.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.2","spread":null},{"groupId":"OG001","value":"76.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.5","spread":null},{"groupId":"OG001","value":"77.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 2: Percentage of Participants Avoiding a Loss of >0 Letters in BCVA From Week 24 in the Study Eye at Specified Timepoints Through Week 72","description":"Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \\[baseline BCVA (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and rest of the world)\\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.4","spread":null},{"groupId":"OG001","value":"51.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.4","spread":null},{"groupId":"OG001","value":"54.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.1","spread":null},{"groupId":"OG001","value":"52.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.2","spread":null},{"groupId":"OG001","value":"55.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.4","spread":null},{"groupId":"OG001","value":"56.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.8","spread":null},{"groupId":"OG001","value":"56.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.8","spread":null},{"groupId":"OG001","value":"58.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.2","spread":null},{"groupId":"OG001","value":"57.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.0","spread":null},{"groupId":"OG001","value":"60.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.0","spread":null},{"groupId":"OG001","value":"56.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.9","spread":null},{"groupId":"OG001","value":"58.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.0","spread":null},{"groupId":"OG001","value":"58.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 2: Percentage of Participants on Different Treatment Intervals at Week 68","description":"In Part 2 of the study, participants in both the faricimab Q4W and aflibercept Q4W arms in Part 1 received 6 mg faricimab intravitreal injections administered according to a personalized treatment interval (PTI) dosing regimen in intervals between Q4W and Q16W. At faricimab dosing visits, treatment intervals were maintained or adjusted (i.e., increased by 4 weeks or decreased by 4, 8, or 12 weeks), based on central subfield thickness (CST) and BCVA values.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.6","spread":null},{"groupId":"OG001","value":"25.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.3","spread":null},{"groupId":"OG001","value":"18.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.7","spread":null},{"groupId":"OG001","value":"9.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.4","spread":null},{"groupId":"OG001","value":"47.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 2: Number of Study Drug Injections Received in the Study Eye From Week 24 Through Week 72","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":null},{"groupId":"OG001","value":"4.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading Scale","description":"This analysis of adverse events (AEs) only includes ocular AEs that occurred in the study eye. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. Ocular AEs of special interest included the following: Suspected transmission of an infectious agent by the study drug; Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, require surgical or medical intervention to prevent permanent loss of sight, or are associated with severe intraocular inflammation (IOI).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"56","spread":null},{"groupId":"OG002","value":"76","spread":null},{"groupId":"OG003","value":"81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"47","spread":null},{"groupId":"OG002","value":"50","spread":null},{"groupId":"OG003","value":"64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"25","spread":null},{"groupId":"OG003","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"7","spread":null},{"groupId":"OG003","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Ocular Adverse Events in the Fellow Eye","description":"This analysis of adverse events (AEs) only includes ocular AEs that occurred in the fellow eye. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. Ocular AEs of special interest included the following: Suspected transmission of an infectious agent by the study drug; Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, require surgical or medical intervention to prevent permanent loss of sight, or are associated with severe intraocular inflammation (IOI).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"21","spread":null},{"groupId":"OG002","value":"37","spread":null},{"groupId":"OG003","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Non-Ocular Adverse Events","description":"This analysis of adverse events (AEs) only includes non-ocular (systemic) AEs. Investigators sought information on adverse events (AEs) at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. The non-ocular AE of special interest was: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"99","spread":null},{"groupId":"OG002","value":"136","spread":null},{"groupId":"OG003","value":"126","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"25","spread":null},{"groupId":"OG003","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Plasma Concentration of Faricimab Over Time","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0000","spread":"0.0000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0215","spread":"0.0160"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0220","spread":"0.0181"},{"groupId":"OG001","value":"0.0005","spread":"0.0006"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0040","spread":"0.0072"},{"groupId":"OG001","value":"0.0025","spread":"0.077"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0061","spread":"0.0110"},{"groupId":"OG001","value":"0.0097","spread":"0.0156"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0076","spread":"0.0109"},{"groupId":"OG001","value":"0.0087","spread":"0.0146"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Anti-Drug Antibodies (ADAs) to Faricimab at Baseline and Post-Baseline During the Study","description":"Anti-drug antibodies (ADAs) against fariciamb were detected in plasma using a validated bridging enzyme-linked immunosorbent assay (ELISA). The number of participants with treatment-emergent ADA-positive samples includes post-baseline evaluable participants with at least one treatment-induced (defined as having an ADA-negative sample or missing sample at baseline and any positive post-baseline sample) or treatment-boosted (defined as having an ADA-positive sample at baseline and any positive post-baseline sample with a titer that is equal to or greater than 4-fold baseline titer) ADA-positive sample during the study treatment period. Treatment-unaffected ADA-positive is a post-baseline sample with a titer that is lower than 4-fold the ADA-positive baseline titer (faricimab arm) or the ADA-positive titer prior to first faricimab injection (aflibercept arm).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"21","spread":null},{"groupId":"OG002","value":"53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":12,"n":276},"commonTop":["COVID-19","Hypertension","Conjunctival haemorrhage","Intraocular pressure increased","Nasopharyngitis"]}}}